Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,800 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 1,800 · Balance 1,800 F1: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 1, 2029. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 1,937 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 1,937 · Balance 1,937 F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 1, 2029.
F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 22:10 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000264 · wk-form4_1783375832.xml · derivative · entry 2 Kimura Koichiro · CIK 0002137620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,937 Underlying: Ordinary Shares · 1,937 shares Expires 2029-06-01 F2 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:10 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantOrdinary Shares | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000264 · wk-form4_1783375832.xml · nonDerivative · entry 1 Kimura Koichiro · CIK 0002137620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 1, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.